Thyme Care and Texas Oncology announced data showing that weight-based dosing of pembrolizumab (Keytruda), delivered under a value-based care agreement, meaningfully reduced cost of care for their shared Medicare Advantage population.
Thyme Care announced the expansion of its Next Chapter Care survivorship program to more than 15,000 members, addressing a challenge that often receives less attention in cancer care: what happens after treatment ends.
